GlassScriptPhysician profile
Kellie Ann Nielsen
NPI 1992154777
$3,665.02
in general payments reported to CMS, 2019-2025
36 companies · $958 in 2025
The $958 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $434 · 2023: $835 · 2024: $1,033 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.36 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.57 | 2023-2025 | Trintellix |
| Lundbeck LLC | $214.78 | 2021-2025 | Rexulti |
| Grifols USA, LLC | $182.12 | 2023-2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $150.50 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $90.68 | 2021-2024 | Spravato |
| Amgen INC. | $89.24 | 2024-2025 | Evenity, Prolia |
| Corium, LLC | $85.15 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $83.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $80.98 | 2021-2025 | Farxiga, Breztri |
| Pfizer INC. | $72.14 | 2021-2024 | |
| Novo Nordisk INC | $63.28 | 2023-2025 | Wegovy |
| Organon LLC | $60.07 | 2021-2025 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.98 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.98 | 2021-2024 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $49.08 | 2025 | Korlym |
| Astellas Pharma US INC | $43.44 | 2022-2024 | Veozah |
| Lilly USA, LLC | $41.26 | 2022-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $40.31 | 2022-2024 | Auvelity |
| Exact Sciences Corporation | $36.66 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $36.56 | 2021 | |
| Alkermes, INC. | $34.73 | 2025 | Aristada, Lybalvi |
| Tris Pharma INC | $30.74 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $29.45 | 2023 | Quviviq |
| Dexcom, INC. | $28.95 | 2024 | Dexcom G6 Transmitter |
| Alfasigma USA, INC. | $27.53 | 2021 | |
| Qol Medical, LLC | $25.08 | 2024 | Sucraid |
| Glaxosmithkline, LLC. | $15.89 | 2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $15.04 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.52 | 2024 | |
| Mayne Pharma Commercial LLC | $14.39 | 2023 | |
| Lucid Diagnostics INC. | $14.13 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.08 | 2025 | Uzedy |
| Inspire Medical Systems, INC. | $13.40 | 2023 | Inspire |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Eisai INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Nielsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.